通过数字包容和虚拟游戏管理预防认知衰退:一项针对社区中老年人的干预研究
Ana Cláudia Bonilha1, Lemmy Willian Ribeiro1, Marcelo Mapurunga1
1Department of Preventive Medicine, Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.
Aging & mental health
|September 15, 2023
概括
数字包容和视频游戏显著改善了老年人的认知功能. 这项干预措施显示,蒙特利尔认知评估 (MoCA) 在四个月内得分显著增加.
科学领域:
- 老年学是一门学科.
- 认知神经科学 认知神经科学
- 数字健康数字健康
背景情况:
- 认知能力下降是人口老龄化的一个重大问题.
- 数字包容性倡议旨在弥合老年人的技术差距.
- 视频游戏对老年人认知刺激的潜力是一个新兴的研究领域.
研究的目的:
- 评估数字包容和视频游戏实践对老年人认知功能的影响.
- 将数字干预与认知正念研讨会的影响进行比较.
主要方法:
- 在人口队列研究中嵌入的随机对照试验.
- 纳入标准:年龄在60岁以上,临床痴呆评分 (CDR) 分数为0或0.5.5的个体.
- 干预组 (IG):62名参与者每周进行1.5小时的计算机活动,持续4个月. 控制组 (CG):47名参与者参加了为期4个月的每周正念研讨会.
- 在干预前后使用蒙特利尔认知评估 (MoCA) 进行神经心理评估.
主要成果:
- 数字素养干预组在干预后的MoCA中平均增加了2.6个点.
- 较高的基线MoCA得分与干预后MoCA得分的较小增加有关.
- 与低学历或高学历的人相比,具有平均学历水平的个人在MoCA分数中经历了更大的改善.
结论:
- 数字包容,特别是与视频游戏实践相结合时,显示出增强老年人认知功能的前景.
- 这些发现表明,有针对性的数字干预可以有效地支持老年人群的认知健康.
相关概念视频
Cognitive Development During Adulthood
155
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
155
Community Based Intervention
65
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
65
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
151
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
151
Aging
86
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
86
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517


